Paul Monahan

Paul Monahan

Company: Spark Therapeutics

Job title: Clinical and Translational Lead, Hematology


Paul Monahan is Translational and Clinical Development Lead for Hematology at Spark Therapeutics.

Prior to 2015, Dr. Monahan was Professor of Pediatrics, Hematology/Oncology at the University of North Carolina at Chapel Hill, where he spent 20 years as an Investigator in the UNC Gene Therapy Center and treating children with bleeding disorders in the Harold Roberts Hemophilia Treatment Center. For ten years he served on the Medical and Scientific Advisory Committee of the National Hemophilia Foundation and as the Region IV Director for the US Hemophilia Treatment Center Network. From 1996 through 2016 his basic science laboratory maintained a research focus on gene therapy for hemophilia as well as animal models for the study of hemophilic bone and joint disease, inhibitors in hemophilia B, and novel therapies. Prior to joining Spark in Spring 2018, he worked in the preclinical development and clinical trial initiation of hemophilia B and hemophilia A gene therapy trials in partnership with Asklepios Biopharmaceuticals and as Medical lead at Baxalta/Shire.


Exploring Hemophilia-Specific Recruitment Challenges 11:30 am

Discussing eligibility of patients with neutralizing antibodies to the proposed AAV vector Evaluating how the number of hemophilia clinical trials impacts recruitment Determining whether current treatment is adequate for the hemophilia communityRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.